JP2014240404A5 - - Google Patents

Download PDF

Info

Publication number
JP2014240404A5
JP2014240404A5 JP2014154372A JP2014154372A JP2014240404A5 JP 2014240404 A5 JP2014240404 A5 JP 2014240404A5 JP 2014154372 A JP2014154372 A JP 2014154372A JP 2014154372 A JP2014154372 A JP 2014154372A JP 2014240404 A5 JP2014240404 A5 JP 2014240404A5
Authority
JP
Japan
Prior art keywords
seq
regulatory
cell epitope
cell
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014154372A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014240404A (ja
JP6121369B2 (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2014240404A publication Critical patent/JP2014240404A/ja
Publication of JP2014240404A5 publication Critical patent/JP2014240404A5/ja
Application granted granted Critical
Publication of JP6121369B2 publication Critical patent/JP6121369B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014154372A 2007-01-30 2014-07-30 調節性ｔ細胞エピトープ、組成物およびその使用 Expired - Fee Related JP6121369B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US89834707P 2007-01-30 2007-01-30
US60/898,347 2007-01-30

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2011247226A Division JP5643739B2 (ja) 2007-01-30 2011-11-11 調節性ｔ細胞エピトープ、組成物およびその使用

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017064298A Division JP6472476B2 (ja) 2007-01-30 2017-03-29 調節性ｔ細胞エピトープ、組成物およびその使用

Publications (3)

Publication Number Publication Date
JP2014240404A JP2014240404A (ja) 2014-12-25
JP2014240404A5 true JP2014240404A5 (enExample) 2015-02-12
JP6121369B2 JP6121369B2 (ja) 2017-04-26

Family

ID=39674696

Family Applications (10)

Application Number Title Priority Date Filing Date
JP2009548278A Expired - Fee Related JP4866467B2 (ja) 2007-01-30 2008-01-29 調節性ｔ細胞エピトープ、組成物およびその使用
JP2011247226A Expired - Fee Related JP5643739B2 (ja) 2007-01-30 2011-11-11 調節性ｔ細胞エピトープ、組成物およびその使用
JP2014154372A Expired - Fee Related JP6121369B2 (ja) 2007-01-30 2014-07-30 調節性ｔ細胞エピトープ、組成物およびその使用
JP2017064298A Expired - Fee Related JP6472476B2 (ja) 2007-01-30 2017-03-29 調節性ｔ細胞エピトープ、組成物およびその使用
JP2019008352A Pending JP2019089793A (ja) 2007-01-30 2019-01-22 調節性ｔ細胞エピトープ、組成物およびその使用
JP2021011596A Withdrawn JP2021073255A (ja) 2007-01-30 2021-01-28 調節性ｔ細胞エピトープ、組成物およびその使用
JP2021072455A Pending JP2021107444A (ja) 2007-01-30 2021-04-22 調節性ｔ細胞エピトープ、組成物およびその使用
JP2021072446A Pending JP2021107443A (ja) 2007-01-30 2021-04-22 調節性ｔ細胞エピトープ、組成物およびその使用
JP2022155804A Pending JP2022177270A (ja) 2007-01-30 2022-09-29 調節性ｔ細胞エピトープ、組成物およびその使用
JP2024033497A Pending JP2024059975A (ja) 2007-01-30 2024-03-06 調節性ｔ細胞エピトープ、組成物およびその使用

Family Applications Before (2)

Application Number Title Priority Date Filing Date
JP2009548278A Expired - Fee Related JP4866467B2 (ja) 2007-01-30 2008-01-29 調節性ｔ細胞エピトープ、組成物およびその使用
JP2011247226A Expired - Fee Related JP5643739B2 (ja) 2007-01-30 2011-11-11 調節性ｔ細胞エピトープ、組成物およびその使用

Family Applications After (7)

Application Number Title Priority Date Filing Date
JP2017064298A Expired - Fee Related JP6472476B2 (ja) 2007-01-30 2017-03-29 調節性ｔ細胞エピトープ、組成物およびその使用
JP2019008352A Pending JP2019089793A (ja) 2007-01-30 2019-01-22 調節性ｔ細胞エピトープ、組成物およびその使用
JP2021011596A Withdrawn JP2021073255A (ja) 2007-01-30 2021-01-28 調節性ｔ細胞エピトープ、組成物およびその使用
JP2021072455A Pending JP2021107444A (ja) 2007-01-30 2021-04-22 調節性ｔ細胞エピトープ、組成物およびその使用
JP2021072446A Pending JP2021107443A (ja) 2007-01-30 2021-04-22 調節性ｔ細胞エピトープ、組成物およびその使用
JP2022155804A Pending JP2022177270A (ja) 2007-01-30 2022-09-29 調節性ｔ細胞エピトープ、組成物およびその使用
JP2024033497A Pending JP2024059975A (ja) 2007-01-30 2024-03-06 調節性ｔ細胞エピトープ、組成物およびその使用

Country Status (11)

Country Link
US (18) US7884184B2 (enExample)
EP (13) EP2450369A1 (enExample)
JP (10) JP4866467B2 (enExample)
KR (3) KR20100014871A (enExample)
CN (4) CN112279911A (enExample)
AT (1) ATE525392T1 (enExample)
AU (1) AU2008211227B2 (enExample)
CA (6) CA3161849A1 (enExample)
IL (3) IL200129A (enExample)
MX (3) MX2009008230A (enExample)
WO (1) WO2008094538A2 (enExample)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2008211227B2 (en) 2007-01-30 2014-04-17 Epivax, Inc. Regulatory T cell epitopes, compositions and uses thereof
DE102007030904A1 (de) * 2007-07-03 2009-02-05 Pharis Biotec Gmbh Humanes zirkulierendes antivirales Albumin-Fragment (ALB-408) und seine Verwendung
EP3578205A1 (en) 2010-08-06 2019-12-11 ModernaTX, Inc. A pharmaceutical formulation comprising engineered nucleic acids and medical use thereof
EP4108671B1 (en) 2010-10-01 2024-11-20 ModernaTX, Inc. Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
CN103561771B (zh) 2011-03-17 2019-01-04 伯明翰大学 重新定向的免疫治疗
JP2014511687A (ja) 2011-03-31 2014-05-19 モデルナ セラピューティクス インコーポレイテッド 工学操作された核酸の送達および製剤
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
PL3682905T3 (pl) 2011-10-03 2022-04-04 Modernatx, Inc. Modyfikowane nukleozydy, nukleotydy i kwasy nukleinowe oraz ich zastosowania
EP2790715B1 (en) * 2011-12-13 2016-12-07 Centre National De La Recherche Scientifique Modified peptides and their use for treating autoimmune diseases
PL2791160T3 (pl) 2011-12-16 2022-06-20 Modernatx, Inc. Kompozycje zmodyfikowanego mrna
GB201203442D0 (en) 2012-02-28 2012-04-11 Univ Birmingham Immunotherapeutic molecules and uses
WO2013151665A2 (en) 2012-04-02 2013-10-10 modeRNA Therapeutics Modified polynucleotides for the production of proteins associated with human disease
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US10501512B2 (en) 2012-04-02 2019-12-10 Modernatx, Inc. Modified polynucleotides
RS63237B1 (sr) 2012-11-26 2022-06-30 Modernatx Inc Terminalno modifikovana rnk
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
WO2015048744A2 (en) 2013-09-30 2015-04-02 Moderna Therapeutics, Inc. Polynucleotides encoding immune modulating polypeptides
JP2016538829A (ja) 2013-10-03 2016-12-15 モデルナ セラピューティクス インコーポレイテッドＭｏｄｅｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． 低密度リポタンパク質受容体をコードするポリヌクレオチド
NZ721105A (en) * 2013-12-06 2022-04-29 Broad Inst Inc Formulations for neoplasia vaccines
LT4023249T (lt) 2014-04-23 2025-01-10 Modernatx, Inc. Nuleorūgšties vakcinos
WO2016054114A1 (en) 2014-09-29 2016-04-07 The Regents Of The University Of California Compositions for expanding regulatory t cells (treg), and treating autoimmune and inflammatory diseases and conditions
US10213482B2 (en) 2014-12-12 2019-02-26 Immupharma France Sa Methods of treating chronic inflammatory diseases
CN107427590B (zh) 2015-02-02 2021-08-31 伯明翰大学 具有多个t细胞表位的靶向部分肽表位复合物
US20180179256A1 (en) * 2015-05-04 2018-06-28 Epivax, Inc. Modified H7 Hemagglutinin Glycoprotein of the Influenza A/Shanghai/2/2013 H7 Sequence
AU2016258929B2 (en) 2015-05-04 2020-10-08 Epivax, Inc. Modified H7 hemagluttinin glycoprotein of the influenza A/Shanghai/2/2013 H7 sequence
US10035856B2 (en) 2015-11-19 2018-07-31 Revitope Limited Functional antibody fragment complementation for a two-components system for redirected killing of unwanted cells
PL238939B1 (pl) * 2016-11-02 2021-10-18 Instytut Immunologii I Terapii Doświadczalnej Polskiej Akademii Nauk Im Ludwika Hirszfelda We Wrocławiu Peptyd immunosupresyjny i jego zastosowania
CA3077084A1 (en) * 2017-10-05 2019-04-11 Epivax, Inc. Regulatory t cell epitopes
EP3622962A1 (en) * 2018-09-14 2020-03-18 advanceCOR GmbH Short cyclic peptides for the treatment of graves' disease
EP3963335B1 (en) * 2019-05-03 2024-08-21 Epivax Therapeutics, Inc. Neoantigens in cancer
US11911414B2 (en) 2020-03-27 2024-02-27 Epivax Inc. Regulatory T cell epitopes
JP2023519347A (ja) * 2020-03-27 2023-05-10 ビオテスト・アクチエンゲゼルシャフト 少なくとも１つの制御性ｔ細胞活性化エピトープを含むタンパク質
CN111856020B (zh) * 2020-06-19 2022-09-27 南方医科大学南方医院 乙型肝炎病毒（hbv）特异性t细胞检测方法及其应用
EP4196232A2 (en) * 2020-08-13 2023-06-21 Epivax, Inc. Regulatory t cell epitopes
US20240173377A1 (en) * 2020-09-25 2024-05-30 Epivax, Inc. Retro - inverso regulatory t cell epitopes
AU2021456003A1 (en) 2021-07-16 2024-02-15 Dbv Technologies Immunotherapeutic method for increasing cashew tolerance in a subject
WO2024240690A2 (en) 2023-05-19 2024-11-28 Numab Therapeutics AG Antibody variable domains and antibodies having decreased immunogenicity

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
FR2556219B1 (fr) 1983-12-07 1987-06-26 Merieux Inst Nouveau medicament immunomodulateur, a base de fragments fc d'igg humaines
GB8725529D0 (en) † 1987-10-30 1987-12-02 Delta Biotechnology Ltd Polypeptides
US5328470A (en) 1989-03-31 1994-07-12 The Regents Of The University Of Michigan Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
US6162432A (en) 1991-10-07 2000-12-19 Biogen, Inc. Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA-3 interaction
FR2686899B1 (fr) † 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
US5817308A (en) * 1994-02-14 1998-10-06 University Of Rochester Tolerogenic fusion proteins of immunoglobulins and methods for inducing and maintaining tolerance
DE4425115A1 (de) 1994-07-15 1996-01-18 Boehringer Mannheim Gmbh Verfahren zur Modifizierung der Stabilität von Antikörpern
US5705154A (en) * 1995-03-08 1998-01-06 Schering Corporation Humanized monoclonal antibodies against human interleukin-4
CA2249320C (en) 1996-03-20 2008-12-23 Immunomedics, Inc. Glycosylated humanized b-cell specific antibodies
US6090381A (en) * 1997-02-11 2000-07-18 Immunomedics, Inc. Stimulation of an immune response with antibodies labeled with the . .alpha-galactosyl epitope
CA2288992C (en) * 1997-04-30 2012-06-12 Enzon, Inc. Single-chain antigen-binding proteins capable of glycosylation, production and uses thereof
US6953675B2 (en) 1997-11-06 2005-10-11 Immunomedics, Inc. Landscaped antibodies and antibody fragments for clinical use
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
AU783037B2 (en) 1999-05-28 2005-09-15 Targeted Genetics Corporation Methods and compositions for lowering the level of tumor necrosis factor (TNF) in the TNF-associated disorders
US6445840B1 (en) 1999-05-28 2002-09-03 Omm, Inc. Micromachined optical switching devices
EP1276856A4 (en) † 2000-04-12 2004-06-09 Human Genome Sciences Inc ALBUMIN FUSION PROTEINS
CA2415902A1 (en) † 2000-07-10 2002-01-17 Xencor Protein design automation for designing protein libraries with altered immunogenicity
BR0208041A (pt) * 2001-03-15 2004-02-25 Merck Patent Gmbh Interferon beta modificado com imunogenicidade reduzida
WO2002079415A2 (en) † 2001-03-30 2002-10-10 Lexigen Pharmaceuticals Corp. Reducing the immunogenicity of fusion proteins
JP4304073B2 (ja) * 2001-11-12 2009-07-29 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング 改変された抗ＴＮＦα抗体
WO2003047618A2 (en) † 2001-12-05 2003-06-12 Circassia Limited Immunotherapeutic methods and systems
JP5424521B2 (ja) † 2001-12-21 2014-02-26 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド アルブミン融合タンパク質
CA2484556A1 (en) † 2001-12-21 2003-07-24 Human Genome Sciences, Inc. Albumin fusion proteins
WO2005003296A2 (en) † 2003-01-22 2005-01-13 Human Genome Sciences, Inc. Albumin fusion proteins
NZ579419A (en) † 2002-02-07 2011-02-25 Dyax Corp Albumin-fused kunitz domain peptides
US7317091B2 (en) * 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
CA2485698C (en) 2002-05-24 2012-03-27 Jin Seog Seo Peptide amidation process
WO2005056606A2 (en) * 2003-12-03 2005-06-23 Xencor, Inc Optimized antibodies that target the epidermal growth factor receptor
US7285269B2 (en) * 2002-12-02 2007-10-23 Amgen Fremont, Inc. Antibodies directed to tumor necrosis factor
CN1511958A (zh) * 2002-12-31 2004-07-14 王小宁 一种筛选人组织相容性抗原(hla)的t细胞表面抗原肽的体系,及其在制备mhc-抗原肽多聚体中的应用
AU2004280333A1 (en) * 2003-08-22 2005-04-21 Medimmune, Llc Humanization of antibodies
WO2005063815A2 (en) 2003-11-12 2005-07-14 Biogen Idec Ma Inc. Fcϝ receptor-binding polypeptide variants and methods related thereto
DK2270045T3 (en) 2004-02-06 2015-04-07 Univ Massachusetts ANTIBODIES AGAINST CLOSTRIDIUM DIFFICILE TOXINES AND APPLICATIONS THEREOF
ES2567634T3 (es) † 2004-02-09 2016-04-25 Human Genome Sciences, Inc. Proteínas de fusión de albúmina
PL1737961T3 (pl) * 2004-03-19 2013-12-31 Merck Patent Gmbh Zmodyfikowane białka bouganiny, cytotoksyny i sposoby oraz ich zastosowania
ZA200608130B (en) * 2004-03-31 2008-12-31 Genentech Inc Humanized anti-TGF-beta antibodies
AU2005271449A1 (en) 2004-08-03 2006-02-16 The Trustees Of Columbia University In The City Of New York RAGE fusion proteins and methods of use
JP5188804B2 (ja) 2004-08-03 2013-04-24 トランステック ファーマ，インコーポレイティド Ｒａｇｅ融合タンパク質及びその使用方法
CU23504A1 (es) * 2004-09-24 2010-04-13 Ct Ingenieria Genetica Biotech Péptidos y derivados tipo apl de la hsp60 y composiciones farmacéuticas
US7488804B2 (en) † 2005-02-02 2009-02-10 The Regents Of The University Of California Modified fusion molecules for treatment of allergic disease
WO2006082406A2 (en) * 2005-02-03 2006-08-10 Antitope Limited Human antibodies and proteins
KR20080032097A (ko) 2005-06-20 2008-04-14 메다렉스, 인코포레이티드 씨디19 항체 및 그의 용도
MX2008001865A (es) † 2005-08-12 2008-04-15 Human Genome Sciences Inc Proteinas de fusion de albumina.
CN100349921C (zh) * 2005-11-17 2007-11-21 中国人民解放军第四军医大学 破伤风毒素t细胞表位多肽与人b淋巴细胞刺激因子融合蛋白及其制备
WO2007076032A2 (en) * 2005-12-20 2007-07-05 Bristol-Myers Squibb Company Compositions and methods for producing a composition
US7951918B2 (en) * 2006-03-17 2011-05-31 Biogen Idec Ma Inc. Stabilized polypeptide compositions
GB0605735D0 (en) 2006-03-22 2006-05-03 Immunobiology Ltd Composition and method for mediating an immune response
US8334365B2 (en) † 2006-06-07 2012-12-18 Human Genome Sciences, Inc. Albumin fusion proteins
AT503861B1 (de) † 2006-07-05 2008-06-15 F Star Biotech Forsch & Entw Verfahren zur manipulation von t-zell-rezeptoren
WO2008021290A2 (en) 2006-08-09 2008-02-21 Homestead Clinical Corporation Organ-specific proteins and methods of their use
AU2008211227B2 (en) * 2007-01-30 2014-04-17 Epivax, Inc. Regulatory T cell epitopes, compositions and uses thereof
KR20100021627A (ko) 2007-06-08 2010-02-25 다우 글로벌 테크놀로지스 인크. Ｃｈ1 도메인의 절단에 의한 가용성 항체 단편의 발현

Similar Documents

Publication Publication Date Title
JP2014240404A5 (enExample)
JP2017165733A5 (enExample)
AR127118A2 (es) Péptidos y combinación de péptidos novedosos para su uso en inmunoterapia contra diversos tumores
WO2015142314A8 (en) Compositions and methods for immunotherapy
EA201790953A1 (ru) Изменение экспрессии гена в cart-клетках и их применения
RU2022103870A (ru) Модифицированный иммунорегуляторный элемент и изменение иммунитета посредством этого элемента
JP2015131795A5 (enExample)
EP4289484A3 (en) Anti-ctla-4 antibodies and methods of use thereof
FI2884999T4 (fi) Menetelmä ja koostumuksia soluimmunoterapiaa varten
EP4219690A3 (en) Methods of cancer treatment using activated t cells
JP2010516290A5 (enExample)
WO2012069568A3 (en) Immunogenic peptides for use in the prevention and/or treatment of infectious diseases, autoimmune diseases, immune responses to allofactors, allergic diseases, tumors, graft rejection and immune responses against viral vectors used for gene therapy or gene vaccination
ZA202206809B (en) Hiv vaccines comprising one or more population episensus antigens
JP2017538401A5 (enExample)
MX392416B (es) Métodos y composiciones para terapia celular adoptiva.
WO2015193359A3 (en) Novel immunotherapy against several tumors of the blood, in particular chronic lymphoid leukemia (cll)
WO2015112749A3 (en) Methods and compositions for antibody and antibody-loaded dendritic cell mediated therapy
EP3456339A3 (en) Novel immunotherapy against several tumors, such as lung cancer including nsclc
WO2015112626A8 (en) Enhanced antigen presenting ability of car t cells by co-introduction of costimulatory molecules
WO2015142675A8 (en) Treatment of cancer using chimeric antigen receptor
JP2018023397A5 (enExample)
JP2017501211A5 (enExample)
WO2016173605A8 (en) Ultra-potent neutralization of cytokines by multispecific antibodies and uses thereof
PE20181897A1 (es) Inmunoterapia contra el melanoma y otros tipos de cancer
JP2016106117A5 (enExample)